Takeda Pharmaceutical Company Ltd is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company in the world. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, ...
Takeda's U.S. clinical development activities are conducted via Takeda Development Center Americas, Inc., which has a robust pipeline of compounds in multiple therapeutic areas including metabolic and cardiovascular diseases, central nervous system, respiratory and immunology, oncology and general medicine.
Contact Reason, Contact Information. Adverse Events and Product Complaints , 877-TAKEDA7 (877-825-3327). Medical Information, 877-TAKEDA7 ...
Takeda Pharmaceuticals U.S.A., Inc. ( TPUSA) is committed to strive toward better health for people worldwide through leading innovation in medicine.
At Takeda, we believe all patients should have access to the medication prescribed by their healthcare providers. We also understand that some patients
Takeda America Holdings, Inc. Business : Holding Company. Address : 767 Third Avenue, New York, NY 10017, USA. Telephone Number : +1-212-421-6954. Fax Number : +1-212-355-5243. Founded : 1997. As a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Takeda America Holdings, Inc.
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology , gastroenterology and central nervous system therapeutic areas plus vaccines.
Takeda Canada Inc. Takeda America Holdings, Inc. Takeda Pharmaceuticals International, Inc. Takeda Pharmaceuticals U.S.A., Inc. Takeda Development Center Americas, Inc. Millennium Pharmaceuticals, Inc. Takeda California, Inc. Takeda Ventures, Inc. Takeda Vaccines, Inc. Takeda Distribuidora Ltda. Multilab Indústria ...
Takeda Pharmaceuticals U.S.A., Inc. announced data highlighting the effectiveness and safety profile of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2016 American College of Gastroenterology (ACG) Annual ...